Intellectual property sharing agreements in gene technology: implications for research and commercialisation Online publication date: Fri, 31-Oct-2014
by Stuart J. Smyth, Richard Gray
International Journal of Intellectual Property Management (IJIPM), Vol. 4, No. 3, 2011
Abstract: In the early 1980s, countries began to allow patenting of biotechnological processes and products, creating technology advancements and rapid development of private industry. Part of the industry development that ensued was a consolidation of small firms and the creation of a few, large life science companies, each owning the requisite intellectual property (IP) and having freedom-to-operate. Despite the ability and potential gains from doing so, for many years there was very little apparent flow of IP between firms, separating potentially complementary technologies. A recent development in the ag-biotech industry, has been the increase in gene trait cross-licensing agreements. While these agreements hold much promise as means to facilitate the much needed sharing of IP, they raise additional concerns with respect to market concentration. This article examines publicly accessible information about the nature of these IP sharing agreements and the incentives they may create.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook